Pancreatic Cancer Research

ResearcherNorth Sichuan Medical UniversityActive in the last 2 years

Yong Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1612-8351; OpenAlex author ID A5100454446. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 11

  1. Genetically predicted blood metabolites mediate the association between circulating inflammation-related proteins and pancreatic cancer Co-author DOI 10.21203/rs.3.rs-5783157/v1↗
  2. Leveraging Diverse Regulated Cell Death for Prognostic Prediction of Pancreatic Cancer Using Machine Learning and Multi-omics Analysis Last author DOI 10.21203/rs.3.rs-3639799/v1↗
  3. Radiomics models based on multi-sequence MRI for preoperative evaluation of MUC4 status in pancreatic ductal adenocarcinoma: a preliminary study. Co-author DOI 10.21037/qims-22-112↗
  4. Radiomics Model Based on MR Images to Discriminate Pancreatic Ductal Adenocarcinoma and Mass-Forming Chronic Pancreatitis Lesions. Co-author DOI 10.3389/fonc.2021.620981↗
  5. Magnetic resonance imaging for preoperative staging of pancreatic cancer based on the 8th edition of AJCC guidelines. Co-author DOI 10.21037/jgo.2020.03.06↗
  6. Role of ubiquitin-conjugating enzyme E2T in the carcinogenesis and progression of pancreatic cancer. Co-author DOI 10.3892/ol.2020.11644↗
  7. Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. Last author DOI 10.1093/jmcb/mjx043↗
  8. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. Last author DOI 10.1002/ijc.30227↗
  9. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  10. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. Co-author DOI 10.1002/emmm.201302507↗
  11. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Co-author DOI 10.1093/carcin/bgt004↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yan Deng · 3 shared papers, 2020–2022 · strength 0.40
  2. Zhaowei Wu · 1 shared paper, 2023 · strength 0.26
  3. Yanheng Duan · 1 shared paper, 2025 · strength 0.26
  4. Liang Jin · 1 shared paper, 2025 · strength 0.26
  5. Jiaze An · 1 shared paper, 2025 · strength 0.26
  6. Bing Ming · 2 shared papers, 2020–2021 · strength 0.25
  7. Xiao Ming Zhang · 2 shared papers, 2020–2021 · strength 0.25
  8. Mengyue Tang · 1 shared paper, 2022 · strength 0.15
  9. Xiaoming Zhang · 1 shared paper, 2022 · strength 0.15
  10. Yong Li · 1 shared paper, 2022 · strength 0.15
  11. Chun‐You Li · 1 shared paper, 2020 · strength 0.15
  12. Yuanwen Zheng · 1 shared paper, 2020 · strength 0.15
  13. Cheng Fang · 2 shared papers, 2016–2017 · strength 0.12
  14. Xin Guo · 2 shared papers, 2016–2017 · strength 0.12
  15. Chuan Lan · 1 shared paper, 2020 · strength 0.12
  16. Xianjun Yu · 3 shared papers, 2013–2015 · strength 0.09
  17. Jingxuan Yang · 2 shared papers, 2013–2015 · strength 0.07
  18. Martín E. Fernández-Zapico · 2 shared papers, 2013–2015 · strength 0.07
  19. Quanxing Ni · 1 shared paper, 2015 · strength 0.04
  20. Aminah Jatoi · 1 shared paper, 2015 · strength 0.04
  21. Angela L. McCleary‐Wheeler · 1 shared paper, 2015 · strength 0.04
  22. Jin Xu · 1 shared paper, 2015 · strength 0.04
  23. Min Li · 1 shared paper, 2015 · strength 0.04
  24. Huaxiang Xu · 1 shared paper, 2015 · strength 0.04
  25. Wenquan Wang · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.